Business Context and Reporting Period
Company: Pavmed Inc. (PAVM)
Filing Type: Form 8-K (Current Report)
Date of Report: February 14, 2025
Event: Notification of regained compliance with Nasdaq continued listing standards.
Key Financial Metrics
This filing does not provide a comprehensive income statement, cash flow statement, or balance sheet. Specific financial metrics disclosed include:
- Stockholders' Equity Requirement: The Company met the Nasdaq standard requiring at least $2.5 million in stockholders' equity.
- Debt Conversion: Secured convertible notes with a principal amount of $22,347,543 were exchanged for Series C convertible preferred stock.
- Capital Raise: Shares of Series C Preferred Stock were issued for an aggregate purchase price of $2.653 million.
Material Changes
The Company resolved a prior deficiency regarding Nasdaq Listing Rule 5550(b)(2) (Market Value of Listed Securities) by regaining compliance under Rule 5550(b)(1) (Stockholders' Equity). Key actions taken to achieve this status include:
- Debt-to-Equity Swap: On January 17, 2025, the Company exchanged $22.35 million in secured convertible notes for Series C Preferred Stock.
- Preferred Stock Issuance: On January 24, 2025, the Company issued Series C Preferred Stock for $2.653 million.
- Deconsolidation: Operating expenses were reduced following the deconsolidation of Lucid Diagnostics Inc. from the Company's balance sheet.
Outlook, Risks, and Contingencies
Mandatory Monitoring: The Company is subject to a Mandatory Panel Monitor for one year (until February 14, 2026) under Nasdaq Listing Rule 5815(d)(4)(B).
Delisting Risk: If the Company fails to maintain compliance with Nasdaq Listing Rule 5550(b)(1) during the monitoring period:
- No plan of compliance will be permitted.
- No additional time for compliance will be granted.
- No automatic cure period will apply.
- Nasdaq staff will issue a delisting letter, requiring a new hearing to avoid removal from the exchange.
Investor Verification Checklist
- Verify the current market value of listed securities to ensure no new market cap deficiencies arise.
- Confirm the terms and conversion mechanics of the newly issued Series C Preferred Stock.
- Monitor future 8-K filings for any updates regarding the Mandatory Panel Monitor status.
- Review the impact of the Lucid Diagnostics Inc. deconsolidation on future revenue recognition and operating expenses.